Akorn, Inc. AKRX today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma's Vancocin®, which is indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD). Vancocin® is also used for the treatment of enterocolitis caused by Staphylococcus aureus including methicillin-resistant strains.
According to IMS Health, Vancocin® 125mg and 250mg had combined sales of approximately $328 million in the U.S. for the twelve months ended December 31, 2011. Akorn has begun shipping its U.S. Food and Drug Administration (FDA) approved generic version in both strengths in a 20 capsule pack size.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in